Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.

Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM.

Leuk Lymphoma. 2013 Mar;54(3):514-9. doi: 10.3109/10428194.2012.720372. Epub 2012 Sep 3.

PMID:
22891708
2.

Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.

Duvic M, Geskin L, Prince HM.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):377-84. doi: 10.1016/j.clml.2013.02.020. Epub 2013 Jun 14.

PMID:
23770157
3.

Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.

Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A.

J Clin Oncol. 2010 Apr 10;28(11):1870-7. doi: 10.1200/JCO.2009.26.2386. Epub 2010 Mar 8.

4.

Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.

Talpur R, Duvic M.

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):180-5. doi: 10.1016/j.clml.2012.01.011. Epub 2012 Apr 21.

PMID:
22521504
5.

Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).

Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A.

Clin Lymphoma. 2002 Mar;2(4):222-8.

PMID:
11970761
6.

Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and S├ęzary syndrome.

Prince HM, Martin AG, Olsen EA, Fivenson DP, Duvic M.

Leuk Lymphoma. 2013 Jan;54(1):69-75. doi: 10.3109/10428194.2012.706286. Epub 2012 Sep 14.

7.

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.

Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L.

Br J Haematol. 2007 Feb;136(3):439-47.

PMID:
17233846
8.

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J.

J Clin Oncol. 2001 Jan 15;19(2):376-88.

PMID:
11208829
9.

Denileukin diftitox.

Figgitt DP, Lamb HM, Goa KL.

Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. Review.

PMID:
11702307
10.
11.

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.

Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L.

J Clin Oncol. 2004 Oct 15;22(20):4095-102. Epub 2004 Sep 7.

12.
13.

Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.

Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC.

J Am Acad Dermatol. 1998 Jul;39(1):63-73.

PMID:
9674399
14.

Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.

Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD.

Cancer. 2006 May 15;106(10):2158-64.

15.

Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.

McCann S, Akilov OE, Geskin L.

Clin J Oncol Nurs. 2012 Oct;16(5):E164-72. Review.

PMID:
23022942
16.

Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.

Avarbock AB, Loren AW, Park JY, Junkins-Hopkins JM, Choi J, Litzky LA, Rook AH.

Am J Hematol. 2008 Jul;83(7):593-5. doi: 10.1002/ajh.21180.

17.

Denileukin diftitox for the treatment of panniculitic lymphoma.

McGinnis KS, Shapiro M, Junkins-Hopkins JM, Smith M, Lessin SR, Vittorio CC, Rook AH.

Arch Dermatol. 2002 Jun;138(6):740-2. No abstract available.

PMID:
12056952
18.

CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.

Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M.

J Invest Dermatol. 2006 Mar;126(3):575-83.

20.

A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.

Carretero-Margolis CD, Fivenson DP.

J Am Acad Dermatol. 2003 Feb;48(2):275-6.

PMID:
12582402
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk